Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Poland Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44353   clinical trials with a EudraCT protocol, of which   7380   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,502 result(s) found for: Poland Syndrome. Displaying page 9 of 76.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2019-000591-42 Sponsor Protocol Number: ISIS766720-CS3 Start Date*: 2019-06-14
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension Trial of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor Administered Monthly Subcutaneously to Patients with Acromegaly Being Treated with Long-Acting ...
    Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) PL (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003791-13 Sponsor Protocol Number: BP42992 Start Date*: 2022-01-11
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15...
    Medical condition: Dup15q Syndrome
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004850 10083952 Dup15q syndrome LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) PL (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000807-99 Sponsor Protocol Number: 4SC-201-6-2015 Start Date*: 2016-09-15
    Sponsor Name:4SC AG
    Full Title: A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ...
    Medical condition: Advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Prematurely Ended) ES (Ongoing) AT (Completed) BE (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002589-37 Sponsor Protocol Number: SL0008 Start Date*: 2008-07-17
    Sponsor Name:UCB Inc
    Full Title: A Phase IIb, Multi-center, Open-label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease Who Parti...
    Medical condition: systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042945 Systemic lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed) HU (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-002184-14 Sponsor Protocol Number: IM128-027 Start Date*: 2014-12-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of care in the Treatmen...
    Medical condition: Active Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003015-26 Sponsor Protocol Number: AMZ002-002 Start Date*: 2022-04-12
    Sponsor Name:Amzell B.V.
    Full Title: A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of AMZ002, Compared to Vigabatrin, in the Treatment of Infantile Spasms
    Medical condition: Monotherapy for the treatment of infantile spasms (IS) in infants and children 2 months to 24 months of age
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10021750 Infantile spasms PT
    21.1 10029205 - Nervous system disorders 10021751 Infantile spasms, with intractable epilepsy LLT
    20.0 10029205 - Nervous system disorders 10021752 Infantile spasms, without mention of intractable epilepsy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Ongoing) PL (Prematurely Ended) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000894-56 Sponsor Protocol Number: NAK-06 Start Date*: 2014-02-26
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: A 12-week double-blind, randomised, placebo-controlled, parallel group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg...
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    18.0 100000004856 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) IT (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001203-79 Sponsor Protocol Number: IM011021 Start Date*: 2017-12-04
    Sponsor Name:Bristol-Myers Squibb international Corporation
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017968 10042947 Systemic lupus erythematosus synd LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) DE (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-000630-22 Sponsor Protocol Number: TV50717-CNS-30047 Start Date*: 2018-06-05
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children a...
    Medical condition: Tics associated with Tourette Syndrome(TS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Completed) FR (Completed) NL (Ongoing) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003958-86 Sponsor Protocol Number: GS-US-356-5413 Start Date*: 2022-06-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Study of Females Exposed to Eleclazine
    Medical condition: The goal of this study is to follow up with female subjects who received eleclazine in prior clinical trials for ischemic heart disease, ventricular arrhythmia, hypertrophic cardiomyopathy or long ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10055218 Ischemic heart disease LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.1 10007541 - Cardiac disorders 10024803 Long QT syndrome PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) IT (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001808-11 Sponsor Protocol Number: ID-064A202 Start Date*: 2019-01-14
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste...
    Medical condition: Moderate to severe systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) HU (Completed) BG (Completed) PL (Completed) GR (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-005667-25 Sponsor Protocol Number: HGS1006-C1113 Start Date*: 2013-01-22
    Sponsor Name:GlaxoSmithKline, LLC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
    Medical condition: Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) CZ (Completed) EE (Completed) ES (Completed) IT (Completed) PT (Completed) BG (Completed) SK (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-022101-18 Sponsor Protocol Number: H9B-MC-BCDX Start Date*: 2012-05-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X)
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Prematurely Ended) ES (Prematurely Ended) LV (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020859-30 Sponsor Protocol Number: SL0012 Start Date*: 2011-05-25
    Sponsor Name:UCB Inc.
    Full Title: A phase 3, multicenter, open-label, extension study to asssess the safety and tolerability of Epratuzumab treatment in systemic lupus erythematosus subjects (EMBODY 4)
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended) DE (Completed) CZ (Prematurely Ended) GB (Prematurely Ended) HU (Completed) BG (Prematurely Ended) LT (Prematurely Ended) IT (Completed) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004253-22 Sponsor Protocol Number: ALXN2040-PNH-303 Start Date*: 2022-07-04
    Sponsor Name:Alexion Pharmaceuticals Inc.
    Full Title: A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on Therapy to a Complement Component 5 Inhibitor (C5i) in Patients with Paroxysmal Nocturnal Hemoglo...
    Medical condition: Patients with Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005257-12 Sponsor Protocol Number: SGI-110-07 Start Date*: 2017-03-17
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Prev...
    Medical condition: Myelodysplastic syndromes (MDS) Chronic myelomonocytic leukemia (CMML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed) DK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001508-12 Sponsor Protocol Number: CVAY736X2208 Start Date*: 2018-11-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess pharmacodynamics, pharmacokinetics, safety, tolerability and preliminary clinical efficacy of VA...
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007290-20 Sponsor Protocol Number: TMC-BIV-08-03 Start Date*: Information not available in EudraCT
    Sponsor Name:The Medicines Company UK Ltd.
    Full Title: European Ambulance Acute Coronary Syndrome Angiox Trial: EUROMAX
    Medical condition: Patients presenting with ST-Segment Elevation Acute Coronary Syndrome (STE-ACS) planned for a primary Percutaneous Coronary Intervention (PCI) management strategy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    14.1 100000004848 10041894 ST segment elevation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) DK (Completed) FR (Completed) NL (Completed) CZ (Completed) ES (Completed) PL (Completed) IT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2021-002803-37 Sponsor Protocol Number: XC001-1001 Start Date*: 2022-01-20
    Sponsor Name:XyloCor Therapeutics, Inc.
    Full Title: A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor, to the Ischemic ...
    Medical condition: Angina Pectoris Secondary
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10002383 Angina pectoris PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002773-21 Sponsor Protocol Number: EMR700461-023 Start Date*: 2014-02-20
    Sponsor Name:Merck KGaA
    Full Title: A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) BG (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Aug 11 05:49:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA